compound 56 Search Results


compound 56  (Santa Cruz Biotechnology)
85
Santa Cruz Biotechnology compound 56
Compound 56, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/Compound+56/10__1021_slash_jm500827t-588-47-21
Average 85 stars, based on 1 article reviews
compound 56 - by Bioz Stars, 2026-10
85/100 stars
  Buy from Supplier
compound 1  (Chem Impex International)
95
Chem Impex International compound 1
Compound 1, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/Anthra%5B1%2C9-cd%5Dpyrazol-6(2H)-one/pm22452656__bi300112e_si_001-13-0-5
Average 95 stars, based on 1 article reviews
compound 1 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
compound 56  (CEREP Inc)
90
CEREP Inc compound 56
Compound 56, supplied by CEREP Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/compound+56/10__1016_slash_j__bmc__2017__12__015-163-1-8
Average 90 stars, based on 1 article reviews
compound 56 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
compound b  (Rocha labs)
90
Rocha labs compound b
Compound B, supplied by Rocha labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/compound+guaiazulene++56+/us11141390-426-34-40
Average 90 stars, based on 1 article reviews
compound b - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
compound #56  (InterBioScreen Ltd)
90
InterBioScreen Ltd compound #56
Compound #56, supplied by InterBioScreen Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/compound++56/pmc06039432-231-0-2
Average 90 stars, based on 1 article reviews
compound #56 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
56 compounds tested for synergy with erlotinib  (BioBioPha Co Ltd)
90
BioBioPha Co Ltd 56 compounds tested for synergy with erlotinib
Constuction of a stable Ba/F3‐insH cell line. ( a – d ) Flow cytometry results of EGFR expression in transfected cells. ( a ) Forty‐eight hours after electroporation, P0‐C, P0‐S; P24‐C, P24‐S. ( b ) After selection of IL3‐deprivation, BaF3‐C, BaF3‐S, P‐C, P24‐S; ( c ) After first monoclone, BaF3‐C, BaF3‐S, P24‐D6G9‐C, P24‐D6G9‐S; ( d ) After second monoclone; left graph, Ba/F3 cells (as a control); right graph, transfected Ba/F3 cells with EGFR‐insH plasmid; red dotted line, unstained cells; green solid line, cells stained with specific anti‐EGFR antibody, BaF3‐C, Ba‐F3‐S, P24‐D6G9E11‐C, P24‐D6G9E11‐S. ( e ) Western blotting results of EGFR and tubulin; 1. Ba/F3 cells, 2. transfected Ba/F3 cells. ( f ). Transforming ability of EGFR‐insH constructs introduced into Ba/F3 cells, IL3‐independent growth of Ba/F3 and Ba/F3‐insH cells. Values for cells grown without IL3 were normalized to the values for cells grown with IL3; *** P < 0.0001 ( n = 6). –IL3, +IL3. ( g ) Response of Ba/F3‐insH cells to <t>erlotinib,</t> IC 50 value was calculated by GraphPad prism V6 ( n = 6). The transfection experiments were performed three times.
56 Compounds Tested For Synergy With Erlotinib, supplied by BioBioPha Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/56+compounds+tested+for+synergy+with+erlotinib/pmc07396384-32-7-11
Average 90 stars, based on 1 article reviews
56 compounds tested for synergy with erlotinib - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
56,984-compound library  (TimTec LLC)
90
TimTec LLC 56,984-compound library
Constuction of a stable Ba/F3‐insH cell line. ( a – d ) Flow cytometry results of EGFR expression in transfected cells. ( a ) Forty‐eight hours after electroporation, P0‐C, P0‐S; P24‐C, P24‐S. ( b ) After selection of IL3‐deprivation, BaF3‐C, BaF3‐S, P‐C, P24‐S; ( c ) After first monoclone, BaF3‐C, BaF3‐S, P24‐D6G9‐C, P24‐D6G9‐S; ( d ) After second monoclone; left graph, Ba/F3 cells (as a control); right graph, transfected Ba/F3 cells with EGFR‐insH plasmid; red dotted line, unstained cells; green solid line, cells stained with specific anti‐EGFR antibody, BaF3‐C, Ba‐F3‐S, P24‐D6G9E11‐C, P24‐D6G9E11‐S. ( e ) Western blotting results of EGFR and tubulin; 1. Ba/F3 cells, 2. transfected Ba/F3 cells. ( f ). Transforming ability of EGFR‐insH constructs introduced into Ba/F3 cells, IL3‐independent growth of Ba/F3 and Ba/F3‐insH cells. Values for cells grown without IL3 were normalized to the values for cells grown with IL3; *** P < 0.0001 ( n = 6). –IL3, +IL3. ( g ) Response of Ba/F3‐insH cells to <t>erlotinib,</t> IC 50 value was calculated by GraphPad prism V6 ( n = 6). The transfection experiments were performed three times.
56,984 Compound Library, supplied by TimTec LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/56+984+compound+library/pmc02763345-167-1-6
Average 90 stars, based on 1 article reviews
56,984-compound library - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
starting iso-cyanides for compounds 56 and 61  (Priaxon Inc)
90
Priaxon Inc starting iso-cyanides for compounds 56 and 61
Constuction of a stable Ba/F3‐insH cell line. ( a – d ) Flow cytometry results of EGFR expression in transfected cells. ( a ) Forty‐eight hours after electroporation, P0‐C, P0‐S; P24‐C, P24‐S. ( b ) After selection of IL3‐deprivation, BaF3‐C, BaF3‐S, P‐C, P24‐S; ( c ) After first monoclone, BaF3‐C, BaF3‐S, P24‐D6G9‐C, P24‐D6G9‐S; ( d ) After second monoclone; left graph, Ba/F3 cells (as a control); right graph, transfected Ba/F3 cells with EGFR‐insH plasmid; red dotted line, unstained cells; green solid line, cells stained with specific anti‐EGFR antibody, BaF3‐C, Ba‐F3‐S, P24‐D6G9E11‐C, P24‐D6G9E11‐S. ( e ) Western blotting results of EGFR and tubulin; 1. Ba/F3 cells, 2. transfected Ba/F3 cells. ( f ). Transforming ability of EGFR‐insH constructs introduced into Ba/F3 cells, IL3‐independent growth of Ba/F3 and Ba/F3‐insH cells. Values for cells grown without IL3 were normalized to the values for cells grown with IL3; *** P < 0.0001 ( n = 6). –IL3, +IL3. ( g ) Response of Ba/F3‐insH cells to <t>erlotinib,</t> IC 50 value was calculated by GraphPad prism V6 ( n = 6). The transfection experiments were performed three times.
Starting Iso Cyanides For Compounds 56 And 61, supplied by Priaxon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/starting+iso+cyanides+for+compounds+56+and+61/us09750719-1035-93-100
Average 90 stars, based on 1 article reviews
starting iso-cyanides for compounds 56 and 61 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
compounds 55 56  (Glycohub Inc)
90
Glycohub Inc compounds 55 56
Constuction of a stable Ba/F3‐insH cell line. ( a – d ) Flow cytometry results of EGFR expression in transfected cells. ( a ) Forty‐eight hours after electroporation, P0‐C, P0‐S; P24‐C, P24‐S. ( b ) After selection of IL3‐deprivation, BaF3‐C, BaF3‐S, P‐C, P24‐S; ( c ) After first monoclone, BaF3‐C, BaF3‐S, P24‐D6G9‐C, P24‐D6G9‐S; ( d ) After second monoclone; left graph, Ba/F3 cells (as a control); right graph, transfected Ba/F3 cells with EGFR‐insH plasmid; red dotted line, unstained cells; green solid line, cells stained with specific anti‐EGFR antibody, BaF3‐C, Ba‐F3‐S, P24‐D6G9E11‐C, P24‐D6G9E11‐S. ( e ) Western blotting results of EGFR and tubulin; 1. Ba/F3 cells, 2. transfected Ba/F3 cells. ( f ). Transforming ability of EGFR‐insH constructs introduced into Ba/F3 cells, IL3‐independent growth of Ba/F3 and Ba/F3‐insH cells. Values for cells grown without IL3 were normalized to the values for cells grown with IL3; *** P < 0.0001 ( n = 6). –IL3, +IL3. ( g ) Response of Ba/F3‐insH cells to <t>erlotinib,</t> IC 50 value was calculated by GraphPad prism V6 ( n = 6). The transfection experiments were performed three times.
Compounds 55 56, supplied by Glycohub Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/compounds+55+56/us09504758-849-0-7
Average 90 stars, based on 1 article reviews
compounds 55 56 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
compound (56)  (ACADEMIC PRESS INC)
90
ACADEMIC PRESS INC compound (56)
Constuction of a stable Ba/F3‐insH cell line. ( a – d ) Flow cytometry results of EGFR expression in transfected cells. ( a ) Forty‐eight hours after electroporation, P0‐C, P0‐S; P24‐C, P24‐S. ( b ) After selection of IL3‐deprivation, BaF3‐C, BaF3‐S, P‐C, P24‐S; ( c ) After first monoclone, BaF3‐C, BaF3‐S, P24‐D6G9‐C, P24‐D6G9‐S; ( d ) After second monoclone; left graph, Ba/F3 cells (as a control); right graph, transfected Ba/F3 cells with EGFR‐insH plasmid; red dotted line, unstained cells; green solid line, cells stained with specific anti‐EGFR antibody, BaF3‐C, Ba‐F3‐S, P24‐D6G9E11‐C, P24‐D6G9E11‐S. ( e ) Western blotting results of EGFR and tubulin; 1. Ba/F3 cells, 2. transfected Ba/F3 cells. ( f ). Transforming ability of EGFR‐insH constructs introduced into Ba/F3 cells, IL3‐independent growth of Ba/F3 and Ba/F3‐insH cells. Values for cells grown without IL3 were normalized to the values for cells grown with IL3; *** P < 0.0001 ( n = 6). –IL3, +IL3. ( g ) Response of Ba/F3‐insH cells to <t>erlotinib,</t> IC 50 value was calculated by GraphPad prism V6 ( n = 6). The transfection experiments were performed three times.
Compound (56), supplied by ACADEMIC PRESS INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/compound++56+/us09527807-454-0-38
Average 90 stars, based on 1 article reviews
compound (56) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
56 compounds  (BioBioPha Co Ltd)
90
BioBioPha Co Ltd 56 compounds
Constuction of a stable Ba/F3‐insH cell line. ( a – d ) Flow cytometry results of EGFR expression in transfected cells. ( a ) Forty‐eight hours after electroporation, P0‐C, P0‐S; P24‐C, P24‐S. ( b ) After selection of IL3‐deprivation, BaF3‐C, BaF3‐S, P‐C, P24‐S; ( c ) After first monoclone, BaF3‐C, BaF3‐S, P24‐D6G9‐C, P24‐D6G9‐S; ( d ) After second monoclone; left graph, Ba/F3 cells (as a control); right graph, transfected Ba/F3 cells with EGFR‐insH plasmid; red dotted line, unstained cells; green solid line, cells stained with specific anti‐EGFR antibody, BaF3‐C, Ba‐F3‐S, P24‐D6G9E11‐C, P24‐D6G9E11‐S. ( e ) Western blotting results of EGFR and tubulin; 1. Ba/F3 cells, 2. transfected Ba/F3 cells. ( f ). Transforming ability of EGFR‐insH constructs introduced into Ba/F3 cells, IL3‐independent growth of Ba/F3 and Ba/F3‐insH cells. Values for cells grown without IL3 were normalized to the values for cells grown with IL3; *** P < 0.0001 ( n = 6). –IL3, +IL3. ( g ) Response of Ba/F3‐insH cells to <t>erlotinib,</t> IC 50 value was calculated by GraphPad prism V6 ( n = 6). The transfection experiments were performed three times.
56 Compounds, supplied by BioBioPha Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/56+compounds/pmc07396384-32-5-11
Average 90 stars, based on 1 article reviews
56 compounds - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
compound 65  (Array BioPharma)
90
Array BioPharma compound 65
Constuction of a stable Ba/F3‐insH cell line. ( a – d ) Flow cytometry results of EGFR expression in transfected cells. ( a ) Forty‐eight hours after electroporation, P0‐C, P0‐S; P24‐C, P24‐S. ( b ) After selection of IL3‐deprivation, BaF3‐C, BaF3‐S, P‐C, P24‐S; ( c ) After first monoclone, BaF3‐C, BaF3‐S, P24‐D6G9‐C, P24‐D6G9‐S; ( d ) After second monoclone; left graph, Ba/F3 cells (as a control); right graph, transfected Ba/F3 cells with EGFR‐insH plasmid; red dotted line, unstained cells; green solid line, cells stained with specific anti‐EGFR antibody, BaF3‐C, Ba‐F3‐S, P24‐D6G9E11‐C, P24‐D6G9E11‐S. ( e ) Western blotting results of EGFR and tubulin; 1. Ba/F3 cells, 2. transfected Ba/F3 cells. ( f ). Transforming ability of EGFR‐insH constructs introduced into Ba/F3 cells, IL3‐independent growth of Ba/F3 and Ba/F3‐insH cells. Values for cells grown without IL3 were normalized to the values for cells grown with IL3; *** P < 0.0001 ( n = 6). –IL3, +IL3. ( g ) Response of Ba/F3‐insH cells to <t>erlotinib,</t> IC 50 value was calculated by GraphPad prism V6 ( n = 6). The transfection experiments were performed three times.
Compound 65, supplied by Array BioPharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+56/compound+56/10__1158_slash_1535___7163__mct___10___0033-75-2-7
Average 90 stars, based on 1 article reviews
compound 65 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Constuction of a stable Ba/F3‐insH cell line. ( a – d ) Flow cytometry results of EGFR expression in transfected cells. ( a ) Forty‐eight hours after electroporation, P0‐C, P0‐S; P24‐C, P24‐S. ( b ) After selection of IL3‐deprivation, BaF3‐C, BaF3‐S, P‐C, P24‐S; ( c ) After first monoclone, BaF3‐C, BaF3‐S, P24‐D6G9‐C, P24‐D6G9‐S; ( d ) After second monoclone; left graph, Ba/F3 cells (as a control); right graph, transfected Ba/F3 cells with EGFR‐insH plasmid; red dotted line, unstained cells; green solid line, cells stained with specific anti‐EGFR antibody, BaF3‐C, Ba‐F3‐S, P24‐D6G9E11‐C, P24‐D6G9E11‐S. ( e ) Western blotting results of EGFR and tubulin; 1. Ba/F3 cells, 2. transfected Ba/F3 cells. ( f ). Transforming ability of EGFR‐insH constructs introduced into Ba/F3 cells, IL3‐independent growth of Ba/F3 and Ba/F3‐insH cells. Values for cells grown without IL3 were normalized to the values for cells grown with IL3; *** P < 0.0001 ( n = 6). –IL3, +IL3. ( g ) Response of Ba/F3‐insH cells to erlotinib, IC 50 value was calculated by GraphPad prism V6 ( n = 6). The transfection experiments were performed three times.

Journal: Thoracic Cancer

Article Title: Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation

doi: 10.1111/1759-7714.13487

Figure Lengend Snippet: Constuction of a stable Ba/F3‐insH cell line. ( a – d ) Flow cytometry results of EGFR expression in transfected cells. ( a ) Forty‐eight hours after electroporation, P0‐C, P0‐S; P24‐C, P24‐S. ( b ) After selection of IL3‐deprivation, BaF3‐C, BaF3‐S, P‐C, P24‐S; ( c ) After first monoclone, BaF3‐C, BaF3‐S, P24‐D6G9‐C, P24‐D6G9‐S; ( d ) After second monoclone; left graph, Ba/F3 cells (as a control); right graph, transfected Ba/F3 cells with EGFR‐insH plasmid; red dotted line, unstained cells; green solid line, cells stained with specific anti‐EGFR antibody, BaF3‐C, Ba‐F3‐S, P24‐D6G9E11‐C, P24‐D6G9E11‐S. ( e ) Western blotting results of EGFR and tubulin; 1. Ba/F3 cells, 2. transfected Ba/F3 cells. ( f ). Transforming ability of EGFR‐insH constructs introduced into Ba/F3 cells, IL3‐independent growth of Ba/F3 and Ba/F3‐insH cells. Values for cells grown without IL3 were normalized to the values for cells grown with IL3; *** P < 0.0001 ( n = 6). –IL3, +IL3. ( g ) Response of Ba/F3‐insH cells to erlotinib, IC 50 value was calculated by GraphPad prism V6 ( n = 6). The transfection experiments were performed three times.

Article Snippet: The 56 compounds tested for synergy with erlotinib were obtained from BioBioPha Co., Ltd. (Kunming China).

Techniques: Flow Cytometry, Expressing, Transfection, Electroporation, Selection, Plasmid Preparation, Staining, Western Blot, Construct

Synergistic inhibition potential of natural compounds with erlotinib in Ba/F3‐insH cells. ( a ) Result from a combination screen across 56 natural compounds with erlotinib; synergy is based on enhancement of growth inhibition compared to either compound alone. ( b ) Result of indicated concentrations of lupalbigenin (LB) with erlotinib. ( c ) Result of indicated concentrations of EA with erlotinib. ( d ) Dose response curve of EA in Ba/F3‐insH cells. ( e ) Dose‐dependent response of Ba/F3‐insH cells to erlotinib in the presence of serial concentrations of EA. The concentration‐dependent assay of EA with erlotinib was performed three times, DMSO, EA (1 μM), EA (5 μM), EA (10 μM).

Journal: Thoracic Cancer

Article Title: Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation

doi: 10.1111/1759-7714.13487

Figure Lengend Snippet: Synergistic inhibition potential of natural compounds with erlotinib in Ba/F3‐insH cells. ( a ) Result from a combination screen across 56 natural compounds with erlotinib; synergy is based on enhancement of growth inhibition compared to either compound alone. ( b ) Result of indicated concentrations of lupalbigenin (LB) with erlotinib. ( c ) Result of indicated concentrations of EA with erlotinib. ( d ) Dose response curve of EA in Ba/F3‐insH cells. ( e ) Dose‐dependent response of Ba/F3‐insH cells to erlotinib in the presence of serial concentrations of EA. The concentration‐dependent assay of EA with erlotinib was performed three times, DMSO, EA (1 μM), EA (5 μM), EA (10 μM).

Article Snippet: The 56 compounds tested for synergy with erlotinib were obtained from BioBioPha Co., Ltd. (Kunming China).

Techniques: Inhibition, Concentration Assay

Effect of EA with erlotinib on the growth of Ba/F3‐insH cells. ( a , b ) Graphs of trypan blue staining after treatment with the indicated concentrations of EA with erlotinib for 48 hours ( a ) and 72 hours ( b ). The experiment was performed three times.

Journal: Thoracic Cancer

Article Title: Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation

doi: 10.1111/1759-7714.13487

Figure Lengend Snippet: Effect of EA with erlotinib on the growth of Ba/F3‐insH cells. ( a , b ) Graphs of trypan blue staining after treatment with the indicated concentrations of EA with erlotinib for 48 hours ( a ) and 72 hours ( b ). The experiment was performed three times.

Article Snippet: The 56 compounds tested for synergy with erlotinib were obtained from BioBioPha Co., Ltd. (Kunming China).

Techniques: Staining

Effect of EA with erlotinib on clonogenic potential of Ba/F3‐insH cells. Colonies were stained with crystal violate 11 days after treatment with the indicated compounds. The result was representative of two independent experiments.

Journal: Thoracic Cancer

Article Title: Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation

doi: 10.1111/1759-7714.13487

Figure Lengend Snippet: Effect of EA with erlotinib on clonogenic potential of Ba/F3‐insH cells. Colonies were stained with crystal violate 11 days after treatment with the indicated compounds. The result was representative of two independent experiments.

Article Snippet: The 56 compounds tested for synergy with erlotinib were obtained from BioBioPha Co., Ltd. (Kunming China).

Techniques: Staining

Effect of EA with erlotinib on Ba/F3‐insH cell apoptosis. ( a , b ) Flow cytometry analysis of cells stained with annexin V and propidium iodide (PI) after treatment with the indicated combinations for ( a ) 48 hours and ( b ) 72 hours. ( c ) Western blotting analysis of cells after treatment with the indicated combinations for 24 hours. Result of flow cytometry analysis was representative of three independent experiments, and the western blot analysis was performed twice.

Journal: Thoracic Cancer

Article Title: Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation

doi: 10.1111/1759-7714.13487

Figure Lengend Snippet: Effect of EA with erlotinib on Ba/F3‐insH cell apoptosis. ( a , b ) Flow cytometry analysis of cells stained with annexin V and propidium iodide (PI) after treatment with the indicated combinations for ( a ) 48 hours and ( b ) 72 hours. ( c ) Western blotting analysis of cells after treatment with the indicated combinations for 24 hours. Result of flow cytometry analysis was representative of three independent experiments, and the western blot analysis was performed twice.

Article Snippet: The 56 compounds tested for synergy with erlotinib were obtained from BioBioPha Co., Ltd. (Kunming China).

Techniques: Flow Cytometry, Staining, Western Blot

Inhibition effect of EA with erlotinib in a xenograft model of Ba/F3‐insH cells. ( a ) Growth of tumors treated with vehicle, 20 mg/kg EA, 100 mg/kg erlotinib or combination for 16 days, *comparison of combination to vehicle or EA alone, Vehicle, Ellagic acid, Erlotinib, Combination. ( b ) Change of bodyweight in the period of feeding. ( c ) Photograph of tumors after mice were sacrificed. ( d ) A quantitative morphometric analysis of tumor size. ( e , f ) Tumor weight ( e ) and value of tumor weight/bodyweight ( f ) after the mice were sacrificed. Animal experiments were performed once.

Journal: Thoracic Cancer

Article Title: Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation

doi: 10.1111/1759-7714.13487

Figure Lengend Snippet: Inhibition effect of EA with erlotinib in a xenograft model of Ba/F3‐insH cells. ( a ) Growth of tumors treated with vehicle, 20 mg/kg EA, 100 mg/kg erlotinib or combination for 16 days, *comparison of combination to vehicle or EA alone, Vehicle, Ellagic acid, Erlotinib, Combination. ( b ) Change of bodyweight in the period of feeding. ( c ) Photograph of tumors after mice were sacrificed. ( d ) A quantitative morphometric analysis of tumor size. ( e , f ) Tumor weight ( e ) and value of tumor weight/bodyweight ( f ) after the mice were sacrificed. Animal experiments were performed once.

Article Snippet: The 56 compounds tested for synergy with erlotinib were obtained from BioBioPha Co., Ltd. (Kunming China).

Techniques: Inhibition